Literature DB >> 25085010

Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor?

P Wuensch1, A Hahne, R Haidinger, K Meißler, B Tenter, C Stoll, B Senf, J Huebner.   

Abstract

INTRODUCTION: Non-adherence to anti-hormonal therapy is a major problem in gynecologic oncology. Reasons reported are side effects and lack of support. The aim of our study was an analysis of influence of experiences of patients with endocrine therapy and communication and information on this topic and their influence on adherence.
METHODS: We developed a structured questionnaire which was tested in a pilot version and then programmed as online questionnaire and presented to patient members of self-help and breast cancer organizations.
RESULTS: Patients only had received scarce information on endocrine therapy. Only 12.8% stated that their questions were answered in detail, 43.2% got no answers or only non-detailed answers. 76% had side effects limiting functions of daily life. 60% of physicians did not react on these side effects. There is a significant correlation between number and intensity of side effects and non-adherence or disruption of therapy (p = 0.029 and p < 0.01, respectively). Women who reported having received detailed answers to their questions also reported better adherence (p = 0.014).
CONCLUSION: In order to improve adherence, detailed information on side effects and answers in case of symptoms are most important. Physicians should not rely on presenting written information but should mainly engage in direct communication.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25085010     DOI: 10.1007/s00432-014-1779-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  19 in total

1.  Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.

Authors:  Annette Wigertz; Johan Ahlgren; Marit Holmqvist; Tommy Fornander; Jan Adolfsson; Henrik Lindman; Leif Bergkvist; Mats Lambe
Journal:  Breast Cancer Res Treat       Date:  2012-05       Impact factor: 4.872

2.  Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.

Authors:  Larissa Nekhlyudov; Lingling Li; Dennis Ross-Degnan; Anita K Wagner
Journal:  Breast Cancer Res Treat       Date:  2011-08-13       Impact factor: 4.872

3.  Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis.

Authors:  Willemien van de Water; Esther Bastiaannet; Elysée T M Hille; Elma M Meershoek-Klein Kranenbarg; Hein Putter; Caroline M Seynaeve; Robert Paridaens; Anton J M de Craen; Rudi G J Westendorp; Gerrit-Jan Liefers; Cornelis J H van de Velde
Journal:  Oncologist       Date:  2011-12-30

4.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Authors:  A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

5.  Compliance and persistence of endocrine adjuvant breast cancer therapy.

Authors:  Uwe Güth; Mary Elizabeth Myrick; Nerbil Kilic; Serenella Eppenberger-Castori; Seraina Margaretha Schmid
Journal:  Breast Cancer Res Treat       Date:  2012-01       Impact factor: 4.872

6.  Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time.

Authors:  C Cluze; D Rey; L Huiart; M K BenDiane; A D Bouhnik; C Berenger; M P Carrieri; R Giorgi
Journal:  Ann Oncol       Date:  2011-07-25       Impact factor: 32.976

7.  Adherence to tamoxifen over the five-year course.

Authors:  Timothy L Lash; Matthew P Fox; Jennifer L Westrup; Aliza K Fink; Rebecca A Silliman
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

8.  Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

Authors:  Yihang Liu; Jennifer L Malin; Allison L Diamant; Amardeep Thind; Rose C Maly
Journal:  Breast Cancer Res Treat       Date:  2012-12-23       Impact factor: 4.872

9.  Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis.

Authors:  Robin J Bell; Pamela Fradkin; Max Schwarz; Susan R Davis
Journal:  Menopause       Date:  2013-01       Impact factor: 2.953

10.  Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer.

Authors:  L Huiart; S Dell'Aniello; S Suissa
Journal:  Br J Cancer       Date:  2011-04-26       Impact factor: 7.640

View more
  15 in total

1.  Talking About My Care: Detecting Mentions of Hormonal Therapy Adherence Behavior in an Online Breast Cancer Community.

Authors:  Zhijun Yin; Wei Xie; Bradley A Malin
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.

Authors:  Gretchen Kimmick; Sara N Edmond; Hayden B Bosworth; Jeffrey Peppercorn; Paul K Marcom; Kimberly Blackwell; Francis J Keefe; Rebecca A Shelby
Journal:  Breast       Date:  2015-07-16       Impact factor: 4.380

3.  The role of the general practitioner in cancer care: a survey of the patients' perspective.

Authors:  V Lang; S Walter; J Fessler; M J Koester; D Ruetters; J Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-10       Impact factor: 4.553

Review 4.  Local and Systemic Therapies for Breast Cancer Patients: Reducing Short-term Symptoms with the Methods of Integrative Medicine.

Authors:  C C Hack; P Voiß; S Lange; A E Paul; S Conrad; G J Dobos; M W Beckmann; S Kümmel
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-07       Impact factor: 2.915

5.  Prostate cancer patients' report on communication about endocrine therapy and its association with adherence.

Authors:  B Jung; C Stoll; G Feick; F J Prott; J Zell; I Rudolph; J Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2016-02       Impact factor: 4.553

6.  Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.

Authors:  Suzanne C O'Neill; Claudine Isaacs; Filipa Lynce; Deena Mary Atieh Graham; Calvin Chao; Vanessa B Sheppard; Yingjun Zhou; Chunfu Liu; Nandini Selvam; Marc D Schwartz; Arnold L Potosky
Journal:  Breast Cancer Res       Date:  2017-03-31       Impact factor: 6.466

7.  Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients.

Authors:  Yura Lee; Yu Rang Park; Ji Sung Lee; Sae Byul Lee; Il Yong Chung; Byung Ho Son; Sei Hyun Ahn; Jong Won Lee
Journal:  J Breast Cancer       Date:  2019-03-11       Impact factor: 3.588

8.  Tailoring communications to the evolving needs of patients throughout the cancer care trajectory: a qualitative exploration with breast cancer patients.

Authors:  Eun-Jung Shim; Jee Eun Park; Myungsun Yi; Dooyoung Jung; Kwang-Min Lee; Bong-Jin Hahm
Journal:  BMC Womens Health       Date:  2016-10-18       Impact factor: 2.809

9.  Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial.

Authors:  P Chalela; E Munoz; D Inupakutika; S Kaghyan; D Akopian; V Kaklamani; K Lathrop; A Ramirez
Journal:  Contemp Clin Trials Commun       Date:  2018-10-17

10.  Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer.

Authors:  Bertha Alejandra Martinez-Cannon; Andrea Castro-Sanchez; Regina Barragan-Carrillo; Sylvia de la Rosa Pacheco; Alejandra Platas; Alan Fonseca; Yoatzin Vega; Karen Bojorquez-Velazquez; Juan Enrique Bargallo-Rocha; Alejandro Mohar; Cynthia Villarreal-Garza
Journal:  Patient Prefer Adherence       Date:  2021-05-19       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.